The drugmaker delivered solid growth in Q2 and upped its full-year outlook.
News & Analysis: Jazz Pharmaceuticals
Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.
A new small-cell lung cancer drug approval isn't the only thing the company has going for it.
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
JAZZ earnings call for the period ending March 31, 2020.
The drugmaker missed Wall Street top- and bottom-line estimates in the first quarter.
These stocks have a track record of revenue growth, and more is to come.
Will a small change in a drug's method of delivery be enough to generate over $1 billion in new sales?
The coronavirus crash has pushed forward price-to-earnings ratios for these healthcare companies down to between 3 and 7.
History shows that now is a great time to go on the offensive and buy high-quality businesses.